The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer
In the treatment of pancreatic ductal adenocarcinoma (PDAC), comorbidities such as cachexia limit quality of life and survival. Here, the authors show TLR7/8 agonist R848 remodels host and tumour immune responses, promoting survival and attenuating cachexia in murine models of PDAC.
Guardado en:
Autores principales: | Katherine A. Michaelis, Mason A. Norgard, Xinxia Zhu, Peter R. Levasseur, Shamilene Sivagnanam, Shannon M. Liudahl, Kevin G. Burfeind, Brennan Olson, Katherine R. Pelz, Diana M. Angeles Ramos, H. Carlo Maurer, Kenneth P. Olive, Lisa M. Coussens, Terry K. Morgan, Daniel L. Marks |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/32ad424ed67248b39855a6f6ea030e5f |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Publisher Correction: The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer
por: Katherine A. Michaelis, et al.
Publicado: (2019) -
Lipocalin 2 mediates appetite suppression during pancreatic cancer cachexia
por: Brennan Olson, et al.
Publicado: (2021) -
Acta Nº848
por: Banco Central de Chile
Publicado: (2019) -
The TLR7 agonist Imiquimod promote the immunogenicity of msenchymal stem cells
por: Zhang,Li, et al.
Publicado: (2015) -
Response of human periodontal ligament stem cells to IFN-γ and TLR-agonists
por: Oleh Andrukhov, et al.
Publicado: (2017)